TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33115902

Group type: EXPERIMENTAL
Intervention: Web-based questionnaires assessing eating and physical activity behaviours, personal characteristics, and global health status.
Number of subjects: 20000
Study: 33115916

Group type: EXPERIMENTAL
Intervention: Intravenous, deuterated 25(OH)D administration
Number of subjects: 100
Study: 33116195

Group type: EXPERIMENTAL
Intervention: GWI related chronic pain group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Military controls without GWI related diffuse body pain
Number of subjects: 20
Study: 33116464

Group type: EXPERIMENTAL
Intervention: BMI (Body Mass Index)
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1644
Study: 33116533

Group type: EXPERIMENTAL
Intervention: Different intervention groups for MDD subtypes (melancholic, atypical, anxious)
Number of subjects: 750
Study: 33116698

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 33117015

Group type: EXPERIMENTAL
Intervention: Interactive Music Therapy (IMT)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Passive Listening (PL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 133
Study: 33117256

Group type: EXPERIMENTAL
Intervention: Sole stimulation (20 min of IAMZS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined IAMZS (20 min) and medication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sole medication
Number of subjects: 10
Study: 33117281

Group type: EXPERIMENTAL
Intervention: Higher Muscle Mass
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 227
Study: 33117454

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily for one week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance, N=7)
Number of subjects: 8
Study: 33117558

Group type: EXPERIMENTAL
Intervention: VOLITION intervention (half-day training workshop for GPs in shared decision-making and a leaflet for patients)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (standard care without the VOLITION intervention)
Number of subjects: 180
Study: 33117895

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy combined with music therapy (10 therapy sessions and related homework)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 43
Study: 33117961

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation; details on dosage and duration not available.
Number of subjects: 0
Study: 33118017

Group type: EXPERIMENTAL
Intervention: Two-incision and intermuscular (IM) technique
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Intermuscular (IM) technique
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Intermuscular plus two-incision technique
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PRAETORIAN low-risk patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PRAETORIAN score
Number of subjects: 213
Study: 33118101

Group type: EXPERIMENTAL
Intervention: Management of anastomotic leakage after elective colorectal surgery
Number of subjects: 76
Study: 33118160

Group type: COMPARATOR
Intervention: Low protein diet (0.5 to 0.6 g/kg/day)
Number of subjects: 2996

Group type: COMPARATOR
Intervention: Low protein diet (≥ 0.8 g/kg/day)
Number of subjects: 2996

Group type: COMPARATOR
Intervention: Very low protein diet (0.3 to 0.4 g/kg/day)
Number of subjects: 2996
Study: 33118199

Group type: EXPERIMENTAL
Intervention: Hemangiol (propranolol)
Number of subjects: 94
Study: 33118951

Group type: EXPERIMENTAL
Intervention: Self-monitoring-based mHealth intervention
Number of subjects: 28
Study: 33118955

Group type: EXPERIMENTAL
Intervention: Web-based SDM training program that included prenatal screening
Number of subjects: 40

Group type: COMPARATOR
Intervention: Web-based training program focusing on prenatal screening alone
Number of subjects: 40
Study: 33118959

Group type: EXPERIMENTAL
Intervention: selfBACK app in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: usual care alone
Number of subjects: 0
Study: 33119476

Group type: EXPERIMENTAL
Intervention: Olaparib (PARP inhibitor)
Number of subjects: 54
Study: 33119478

Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioimmunotherapy (RIT) with anti-B7H3 murine monoclonal antibody
Number of subjects: 52
Study: 33119479

Group type: EXPERIMENTAL
Intervention: Ivosidenib plus azacitidine
Number of subjects: 23
Study: 33119664

Group type: EXPERIMENTAL
Intervention: Neutrophil extracellular trap components (dsDNA, MPO-DNA, CitH3)
Number of subjects: 61
Study: 33119792

Group type: EXPERIMENTAL
Intervention: Children with significant CHD in the 'Monitor' range (cut-off scores ≤ -1SD)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Children with significant CHD in the 'Refer' range (cut-off scores ≤ -2SD)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overall NDD rate in children with significant CHD
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Presence of non-cardiac disease in children with NDD
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Children with NDD who had no developmental follow-up
Number of subjects: 210
Study: 33121236

Group type: EXPERIMENTAL
Intervention: Danicopan monotherapy (100-200 mg thrice daily)
Number of subjects: 10
Study: 33121535

Group type: EXPERIMENTAL
Intervention: GEMS-H
Number of subjects: 20

Group type: COMPARATOR
Intervention: NoGEMS-H
Number of subjects: 20
Study: 33121725

Group type: EXPERIMENTAL
Intervention: Sugary Drinks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificially-Sweetened Beverages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33121896

Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concentric cycling (CON)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 35
Study: 33121904

Group type: EXPERIMENTAL
Intervention: Mitral calcium volume (MCV) >0 mm
Number of subjects: 0
Study: 33122295

Group type: EXPERIMENTAL
Intervention: Distal pancreatectomy (DP)
Number of subjects: 485
Study: 33122314

Group type: EXPERIMENTAL
Intervention: Surgically treated group
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conservatively treated group
Number of subjects: 1200
Study: 33122336

Group type: EXPERIMENTAL
Intervention: Lung EpiCheck (methylation-based plasma test) with low cut-off (LCO)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lung EpiCheck (methylation-based plasma test) with high cut-off (HCO)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lung EpiCheck (methylation-based plasma test)
Number of subjects: 102
Study: 33122421

Group type: EXPERIMENTAL
Intervention: Planned angiographic control (PAC) strategy performed with CT coronary after 6 months
Number of subjects: 550

Group type: COMPARATOR
Intervention: Conservative symptoms and ischaemia-driven follow-up management
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Planned angiographic control (PAC) strategy
Number of subjects: 550
Study: 33122543

Group type: EXPERIMENTAL
Intervention: Continuous morphine infusions (median duration 20.5 hours) with paracetamol 4 times daily and rescue morphine for unacceptable pain (numerical rating scale ≥4)
Number of subjects: 118
Study: 33122575

Group type: EXPERIMENTAL
Intervention: Preanaesthetic carotid artery FTc measured using Bazett's formula
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Preanaesthetic carotid artery FTc measured using Wodey's formula
Number of subjects: 38
Study: 33122578

Group type: EXPERIMENTAL
Intervention: EGFR-TKIs as adjuvant therapy or neoadjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of MET inhibitors to EGFR-TKIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel compounds targeting EGFR exon 20 insertion (EGFR20ins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-line osimertinib and adjuvant osimertinib
Number of subjects: 0
Study: 33122713

Group type: EXPERIMENTAL
Intervention: Male VIPs
Number of subjects: 7555
Study: 33122898

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Any Triple Combination Therapy
Number of subjects: 0
Study: 33123048

Group type: EXPERIMENTAL
Intervention: Reduced Environmental Stimulation Therapy (REST)
Number of subjects: 0
Study: 33123159

Group type: EXPERIMENTAL
Intervention: Adoptively transferred virus-specific T-cells (VSTs) targeting HPIV3
Number of subjects: 10
Study: 33123384

Group type: EXPERIMENTAL
Intervention: Hepatocyte matrix implant
Number of subjects: 11
Study: 33123725

Group type: EXPERIMENTAL
Intervention: Autistic children
Number of subjects: 67

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 67
Study: 33124005

Group type: EXPERIMENTAL
Intervention: Revefenacin administered via nebulization at dose levels ranging from 22-700 μg
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Revefenacin
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Revefenacin and THRX-195518
Number of subjects: 935
Study: 33124006

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg once daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Etravirine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Antiretroviral drugs with known impact on lipid profile (protease inhibitors, efavirenz, cobicistat)
Number of subjects: 65
Study: 33124646

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33124947

Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy Applications
Number of subjects: 0
Study: 33125295

Group type: EXPERIMENTAL
Intervention: Simplified algorithm for prevention and early treatment of bleeding, differentiation syndrome, and infection; education of oncologists about early deaths in APL; frequent communication between expert and treating physician in the first 2 weeks.
Number of subjects: 120
Study: 33125309

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg and ipilimumab 3 mg/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.
Number of subjects: 35
Study: 33125416

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with AKI (n = 304)
Number of subjects: 1

Group type: COMPARATOR
Intervention: COVID-19-negative patients with AKI (n = 420)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with AKI
Number of subjects: 1

Group type: COMPARATOR
Intervention: COVID-19 patients without AKI
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: COVID-19 AKI patients
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 1
Study: 33125520

Group type: EXPERIMENTAL
Intervention: Senolytic treatment targeting senescent cells
Number of subjects: 227

Group type: COMPARATOR
Intervention: High levels of SA-β-gal in subcutaneous adipose tissue
Number of subjects: 227

Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 227
Study: 33125537

Group type: EXPERIMENTAL
Intervention: Tailored electronic patient-reported outcomes tool (PRO-CTCAE) in addition to standard toxicity monitoring
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard monitoring alone
Number of subjects: 146
Study: 33125909

Group type: EXPERIMENTAL
Intervention: Targeted therapy (taselisib, palbociclib, AZD4547, rilotumumab plus erlotinib, talazoparib, telisotuzumab vedotin)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 or anti-PD-L1 therapy (durvalumab, nivolumab plus ipilimumab)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Docetaxel (second line therapy)
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Targeted therapy
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Anti-PD-1 or anti-PD-L1-containing therapies
Number of subjects: 1864
Study: 33126339

Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg every 3 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 11
Study: 33126634

Group type: EXPERIMENTAL
Intervention: Trained for SNSs use
Number of subjects: 130

Group type: COMPARATOR
Intervention: Untrained for SNSs use
Number of subjects: 130
Study: 33127750

Group type: EXPERIMENTAL
Intervention: Reformulated T3 (2.73 µg T3 in 300 µl for 5 consecutive days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control articles
Number of subjects: 100
Study: 33127856

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 7061
Study: 33128080

Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES)
Number of subjects: 17
Study: 33128179

Group type: COMPARATOR
Intervention: BiV-Late
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Best pacing mode
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Optimized AVD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Optimized SyncAV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nominal SyncAV and MPP
Number of subjects: 30
Study: 33128208

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (28-mg intranasal dose)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Esketamine (various routes: intranasal, intravenous, oral)
Number of subjects: 820
Study: 33128299

Group type: EXPERIMENTAL
Intervention: Pamiparib 20 mg BID
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pamiparib 40 mg BID
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg BID
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 33128347

Group type: EXPERIMENTAL
Intervention: Avacopan 10 mg plus standard-of-care (SOC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg plus standard-of-care (SOC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) only
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg plus SOC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Avacopan 10 mg plus SOC
Number of subjects: 42
Study: 33128785

Group type: EXPERIMENTAL
Intervention: Cytosponge sampling
Number of subjects: 102
Study: 33128796

Group type: EXPERIMENTAL
Intervention: Serum IL-18 levels
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 14
Study: 33128873

Group type: EXPERIMENTAL
Intervention: 4.0 mg CH5126766 three times per week
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3.2 mg CH5126766 three times per week
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4.0 mg CH5126766 twice per week
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4.0 mg CH5126766 (various schedules)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CH5126766
Number of subjects: 58
Study: 33128903

Group type: COMPARATOR
Intervention: Fostemsavir (600 mg twice a day) in combination with failing regimen for 8 days, followed by fostemsavir plus optimised background therapy
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Fostemsavir (600 mg twice a day) plus optimised background therapy from day 1
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Fostemsavir (randomised cohort)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Fostemsavir (non-randomised cohort)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 371
Study: 33129352

Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Matched nodal structures
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unmatched nodal structures
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Malignant nodal structures
Number of subjects: 24
Study: 33129355

Group type: EXPERIMENTAL
Intervention: Perinatal OUD education for healthcare providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perinatal OUD provider education
Number of subjects: 0
Study: 33129688

Group type: EXPERIMENTAL
Intervention: Sapien 3 THV
Number of subjects: 200

Group type: COMPARATOR
Intervention: No HALT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HALT group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 200
Study: 33129735

Group type: EXPERIMENTAL
Intervention: Culprit plaque erosion (PE)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Culprit plaque rupture (PR)
Number of subjects: 523
Study: 33130007

Group type: EXPERIMENTAL
Intervention: Severe/very severe constipation
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Moderate constipation
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: None/very mild/mild constipation
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Delayed colonic transit
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Severity of constipation
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Increasing severity of constipation
Number of subjects: 338
Study: 33130166

Group type: EXPERIMENTAL
Intervention: Neighborhood greenness (measured by NDVI)
Number of subjects: 1178
Study: 33130216

Group type: EXPERIMENTAL
Intervention: CCT3833
Number of subjects: 1
Study: 33130518

Group type: EXPERIMENTAL
Intervention: iNKT+/CD3+ lymphocytes in peripheral blood and tissue specimens
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: iNKT+/CD3+/CD161+ lymphocytes in blood and cancer tissue
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: iNKT cells in blood and intra-tumor NKT-cell infiltration
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: iNKT cells in benign ovarian tumors
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: iNKT cells in tumor tissue
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CA125 serum marker
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NKT lymphocyte count from ovarian tissue
Number of subjects: 80
Study: 33130556

Group type: EXPERIMENTAL
Intervention: Mean follow-up intraocular pressure (IOP) for G1 <21 mmHg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Mean follow-up intraocular pressure (IOP) for G2 <18 mmHg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Mean follow-up intraocular pressure (IOP) for G3 <15 mmHg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Adherence to treatment guidelines
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP for G1
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP for G2
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP for G3
Number of subjects: 603
Study: 33130933

Group type: EXPERIMENTAL
Intervention: Implant Removal (IR)
Number of subjects: 37
Study: 33130961

Group type: EXPERIMENTAL
Intervention: SUVmax
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: SUR
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Qualitative assessment using a five-point ordinal PET-grade
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Combined PET/CT grade using CT features
Number of subjects: 355
Study: 33131027

Group type: EXPERIMENTAL
Intervention: Zolpidem (5 or 10 mg) daily for 2 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: IDSIQ-18
Number of subjects: 114

Group type: COMPARATOR
Intervention: Good sleepers (observational study)
Number of subjects: 114
Study: 33131249

Group type: EXPERIMENTAL
Intervention: M-CLL subset #2 in early-stage cohort
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: M-CLL subset #2 in advanced-stage cohort
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: M-CLL subset #4
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: U-CLL subset #8
Number of subjects: 2453
Study: 33131308

Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy
Number of subjects: 0
Study: 33131426

Group type: EXPERIMENTAL
Intervention: Mobile Interventional Stroke Team (MIST)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Drip-and-ship (DS)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Mothership
Number of subjects: 228
Study: 33131757

Group type: EXPERIMENTAL
Intervention: Increased risk patients (ARISCAT score ≥26)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Lower risk patients (ARISCAT score <26)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Increased risk patients
Number of subjects: 905
Study: 33131912

Group type: EXPERIMENTAL
Intervention: ESBL-producing Enterobacteriaceae infection
Number of subjects: 527

Group type: COMPARATOR
Intervention: Ceftriaxone (empirical antibiotic)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: In vitro-active antibiotics
Number of subjects: 527
Study: 33131933

Group type: EXPERIMENTAL
Intervention: Hantavax® (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hantavax® (booster dose at 13 months)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hantavax® (three primary doses)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hantavax® (booster doses)
Number of subjects: 320
Study: 33132098

Group type: EXPERIMENTAL
Intervention: Healthy vascular aging (HVA) estimated by heart age (HA)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Healthy vascular aging (HVA) estimated by vascular age (VA)
Number of subjects: 501
Study: 33132297

Group type: EXPERIMENTAL
Intervention: Two doses of Men-ACWY-D vaccine administered 8 weeks apart
Number of subjects: 60
Study: 33134423

Group type: EXPERIMENTAL
Intervention: Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ART-naïve people with HIV)
Number of subjects: 0
Study: 33134951

Group type: EXPERIMENTAL
Intervention: Nebulized DAS181 (4.5 mg) twice a day for 10 days
Number of subjects: 3